Capricor Therapeutics (CAPR) Net Income towards Common Stockholders (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Net Income towards Common Stockholders of -$33.9 million for Q1 2026, down 39.15% year-over-year from -$55.8 million in Q1 2025, and down 13.27% quarter-over-quarter from -$30.0 million in Q4 2025.
Capricor Therapeutics (CAPR) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$33.9 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 39.15% year-over-year to -$33.9 million; the TTM figure through Mar 2026 stood at -$212.8 million (down 15.09% YoY), while the FY2025 annual figure was -$105.0 million, down 159.58% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$33.9 million, down from -$30.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$561514.0 in Q4 2023, with the low at -$131.1 million in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$23.1 million (2024), against an average of -$31.2 million.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 93.12% in 2023, then slumped 1133.65% in 2024.
- Capricor Therapeutics' Net Income towards Common Stockholders stood at -$8.2 million in 2022, then surged by 93.12% to -$561514.0 in 2023, then slumped by 1027.8% to -$6.3 million in 2024, then slumped by 373.17% to -$30.0 million in 2025, then slipped by 13.27% to -$33.9 million in 2026.
- Business Quant data shows CAPR's Net Income towards Common Stockholders at -$33.9 million in Q1 2026, -$30.0 million in Q4 2025, and -$60.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -33.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.94 Mn |
| Dec 31, 2025 | -29.96 Mn |
| Sep 30, 2025 | -60.21 Mn |
| Jun 30, 2025 | -88.72 Mn |
| Mar 31, 2025 | -24.39 Mn |
| Dec 31, 2024 | -6.33 Mn |
| Sep 30, 2024 | -131.06 Mn |
| Jun 30, 2024 | -23.15 Mn |
| Mar 31, 2024 | -41.22 Mn |
| Dec 31, 2023 | -561,514.00 |
| Sep 30, 2023 | -10.62 Mn |
| Jun 30, 2023 | -19.48 Mn |
| Mar 31, 2023 | -8.23 Mn |
| Dec 31, 2022 | -8.16 Mn |
| Sep 30, 2022 | -24.24 Mn |
| Jun 30, 2022 | -11.68 Mn |
| Mar 31, 2022 | -7.90 Mn |
| Dec 31, 2021 | -6.23 Mn |
| Sep 30, 2021 | -10.04 Mn |
| Jun 30, 2021 | -5.07 Mn |